Supernus Pharmaceuticals Profit Margin

Supernus Pharmaceuticals (SUPN) currently reports a profit margin of -0.02% as of March 2026. That compares with 9.27% in the prior-year period — down 100.2% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Supernus Pharmaceuticals's profit margin history and peer comparisons.

Supernus Pharmaceuticals's profit margin decreased from 9.27% to -0.02% — a 100.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Supernus Pharmaceuticals's profit margin of -0.02% is lower than the Healthcare sector average of 15.58%. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Supernus Pharmaceuticals's current -0.02% should be judged against Healthcare norms (sector average: 15.58%) and against SUPN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -0.02%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Supernus Pharmaceuticals, and consider following SUPN for alerts when major investors trade the stock.